Fulcrum Therapeutics (FULC)
(Delayed Data from NSDQ)
$7.80 USD
-0.46 (-5.52%)
Updated May 16, 2024 04:00 PM ET
After-Market: $7.81 +0.02 (0.19%) 6:52 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Fulcrum Therapeutics, Inc. [FULC]
Reports for Purchase
Showing records 21 - 31 ( 31 total )
Company: Fulcrum Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Focus Remains on Phase 2b ReDUX4 Data In June, With First Look at FTX-6058 in Mid-21; Reit Buy and $20PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Fulcrum Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Detailed SAR of FTX-6058 Exemplifies FulcrumÂ’s Rational Drug Design
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Fulcrum Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Data Rich 2021 Anticipated, With Platform Progress For Both FSHD and SCD
Provider: H.C. Wainwright & Co., Inc.
Analyst: GLASER GARY
Company: Fulcrum Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
KOL Event Shines Light on Targeting EED Protein for HbF Induction.
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Fulcrum Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Full ReDUX4 Data Expected in 2Q21, With FTX-6058 Phase 1 Initiation Expected by YE20; Reit Buy and $20
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Fulcrum Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Interim Analysis From ReDUX4 Raises Questions on Patient Responses; Reit Buy and Lowering PT to $ 20
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Fulcrum Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Amended ReDUX4 Study Could Provide Further Insights Toward Efficacy; Reit Buy and $28 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Fulcrum Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Progress on Multiple Fronts With Topline FSHD Data on Track to Readout in 3Q20
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Fulcrum Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Looking Ahead to 2020 With Topline Data From Losmapimod Phase 2b Study; Reit Buy and $21 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Fulcrum Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Losmapimod Phase 1 Results Display Preliminary Safety and Target Engagement in FSHD.
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A